Teva Pharmaceuticals' TEV-479 (olanzapine) showed significant improvements in schizophrenia symptoms and quality of life in a Phase III trial. The study revealed positive results across different doses, outperforming the placebo, with potential benefits for patient adherence and management of schizophrenia.